Published in
American Association for the Advancement of Science, Science Translational Medicine, 471(10), 2018
DOI: 10.1126/scitranslmed.aau0417
Links
Tools
MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
Journal article published in 2018 by
Praveen K. Bommareddy 
,
Salvatore Aspromonte,
Andrew Zloza ,
Samuel D. Rabkin ,
Howard L. Kaufman
,
Salvatore Aspromonte,
Andrew Zloza ,
Samuel D. Rabkin ,
Howard L. Kaufman
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Combining oncolytic virus and a MEK inhibitor augments immune-mediated therapeutic responses in melanoma and enhances sensitivity to PD-1 blockade in mice.